Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$0.00

(0.00%)

, NVS

Novartis

$80.51

-1.35 (-1.65%)

08:55
05/14/19
05/14
08:55
05/14/19
08:55

New York Academy of Sciences to hold a conference

Frontiers in Cancer Immunotherapy will be held in New York on May 14-15 with webcasted company presentations to begin on May 14 at 9 am; not all company presentations may be webcasted. Webcast Link

TSRO

Tesaro

$0.00

(0.00%)

NVS

Novartis

$80.51

-1.35 (-1.65%)

DNA

Bought by RHHBY

$0.00

(0.00%)

CELG

Celgene

$94.08

-1.45 (-1.52%)

CTMX

CytomX Therapeutics

$10.83

-0.25 (-2.26%)

PFE

Pfizer

$40.60

-0.12 (-0.29%)

CGEN

Compugen

$3.47

-0.13 (-3.61%)

IMMP

Immutep

$1.93

-0.01 (-0.52%)

CUE

Cue Biopharma

$8.14

0.1 (1.24%)

ANIX

Anixa Biosciences

$4.50

-0.12 (-2.60%)

IOVA

Iovance Biotherapeutics

$10.18

-0.93 (-8.37%)

  • 14

    May

  • 14

    May

  • 16

    May

  • 18

    May

  • 20

    May

  • 23

    May

  • 31

    May

  • 10

    Jun

  • 27

    Jun

  • 03

    Sep

  • 04

    Nov

TSRO Tesaro
$0.00

(0.00%)

12/14/18
LEER
12/14/18
NO CHANGE
LEER
Outperform
Tesaro proxy documents point to interest in PARP economics, says Leerink
Leerink analyst Andrew Berens noted that GlaxoSmithKline (GSK) and Tesaro (TSRO) disclosed background details for their deal agreement in a filing this morning. The documents show several parties were interested in a strategic transaction with Tesaro at various points over the last year, though the strategic interest appears to have been driven by Glaxo and one additional company, identified as "Party A", Berens said. It is not clear why the six other contacted parties were not interested in pursuing a strategic transaction, but he thinks Party A's co-promote proposal and the initial interest of other potential acquirers indicates strategic interest in the economics surrounding a PARP. Berens, who continues to see Clovis (CLVS) being well-positioned as the remaining stand-alone PARP-focused company, keeps an Outperform rating on Clovis and Market Perform rating on Tesaro.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
12/10/18
LEHM
12/10/18
DOWNGRADE
Target $75
LEHM
Equal Weight
Tesaro downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded Tesaro (TSRO) to Equal Weight citing the takeover by GlaxoSmithKline (GSK). The analyst raised her price target for the shares to $75 from $48.
12/05/18
CANT
12/05/18
DOWNGRADE
Target $75
CANT
Neutral
Tesaro downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young downgraded Tesaro (TSRO) to Neutral to reflect the takeover by GlaxoSmithKline (GSK). The analyst raised her price target for the shares to $75 from $68.
NVS Novartis
$80.51

-1.35 (-1.65%)

05/09/19
STFL
05/09/19
NO CHANGE
STFL
Buy
Novartis deal makes Aerie 'look like a steal' at current levels, says Stifel
Stifel analyst Annabel Samimy said Novartis' (NVS) agreement to buy Takeda's (TAK) dry eye product Xiidra for $3.4B upfront in cash and up to an additional $1.9B in potential milestone payments "clearly frames the value for innovative ophthalmologic assets" and makes shares of Aerie Pharmaceuticals (AERI) "look like a steal." Applying the same peak sales multiple that Novartis paid for Xiidra implies a market-value of greater than $6B for Aerie, said Samimy, who noted that she does not expect an immediate takeout of Aerie but remains a buyer of the shares.
05/13/19
CANT
05/13/19
NO CHANGE
Target $405
CANT
Neutral
Regeneron price target lowered to $405 from $441 at Cantor Fitzgerald
Cantor Fitzgerald analyst Regeneron Pharmaceuticals (REGN) to $405 from $441 saying the company's expenses are tracking higher than his projections. Further, he thinks investor concerns about Novartis' (NVS) brolucizumab approval in eye and increased atopic dermatitis competition remain headwinds for share upside. The analyst reiterates a Neutral rating on Regeneron following its Q1 results.
05/13/19
WELS
05/13/19
NO CHANGE
WELS
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."
05/09/19
LEHM
05/09/19
NO CHANGE
Target $245
LEHM
Equal Weight
Barclays cuts Biogen target to $245 on reduced Spinraza estimates
Barclays analyst Geoff Meacham lowered his price target for Biogen (BIIB) to $245 from $250 citing growing uncertainty in spinal muscular atrophy. Concerns over Spinraza in spinal muscular atrophy have intensified with the impending launch of Novartis' (NVS) gene therapy Zolgensma and Roche (RHHBY)/PTC's (PTCT) oral risdiplam, Meacham tells investors in a research note. The analyst says his feedback from key opinion leaders was "direct and unequivocal," with the leaders predicting "robust uptake" of both Zolgensma and risdiplam given signs of improved efficacy. This was at the expense of Spinraza driven by the clinical burden of intrathecal injections, says Meacham. On the basis of this feedback, he lowered his longer-term Spinraza outlook by ~$150M per year. The analyst now forecasts sales of $2.0B in 2019, declining to $1.7B in 2023. He keeps an Equal Weight rating on Biogen.
DNA Bought by RHHBY
$0.00

(0.00%)

CELG Celgene
$94.08

-1.45 (-1.52%)

05/03/19
LEHM
05/03/19
UPGRADE
Target $55
LEHM
Overweight
Bristol-Myers upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoffrey Meacham upgraded Bristol-Myers Squibb (BMY) to Overweight from Equal Weight and raised his price target for the shares to $55 from $53. The analyst says increased confidence in the Celgene (CELG) acquisition successfully closing makes him more bullish on Bristol-Myers shares. Increased optionality from the Celgene pipeline along with a "differentiated" growth profile and earnings power over the next few years make the combined company attractive at current share levels, Meacham tells investors in a research note.
05/03/19
LEHM
05/03/19
DOWNGRADE
Target $102
LEHM
Equal Weight
Celgene downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoffrey Meacham downgraded Celgene (CELG) to Equal Weight from Overweight to reflect his increased confidence that the takeover by Bristol-Myers (BMY) will close. The analyst, who upgraded Bristol-Myers this morning to Overweight, says his thesis on Celgene has played out. He keeps a $102 price target for the shares.
05/03/19
JPMS
05/03/19
INITIATION
Target $62
JPMS
Overweight
Bristol-Myers reinstated with an Overweight at JPMorgan
Following a period of restriction, JPMorgan analyst Chris Schott reinstated coverage of Bristol-Myers Squibb (BMY) with an Overweight rating and $62 price target. The analyst had an Overweight rating on the shares and price target of $70 prior to restriction. While the company's proposed acquisition of Celgene (CELG) has been controversial, the shares are "too inexpensive to ignore," Schott tells investors in a research note. He sees the combined company generating 2020 earnings of $6.50 per share and 3% sales/6% earnings growth off of this base through 2025.
05/07/19
PIPR
05/07/19
NO CHANGE
Target $23
PIPR
Overweight
Sutro regaining U.S. rights from Celgene a 'clear positive,' says Piper Jaffray
The FDA has cleared the investigational new drug application for Sutro Biopharma's Celgene-partnered BCMA ADC, which is on track to enter the clinic in 2019, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. In addition, Celgene not exercise an option on a second program, meaning Sutro has regained U.S. rights, adds the analyst. He views this as a "clear positive" for Sutro, saying the company has regained the U.S. rights to "another exciting preclinical program." Importantly, there is no impact on Sutro's wholly-owned clinical programs, Tenthoff adds. He reiterates an Overweight rating on Sutro Biopharma with a $23 price target.
CTMX CytomX Therapeutics
$10.83

-0.25 (-2.26%)

03/11/19
03/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. TCR2 Therapeutics (TCRR) initiated with an Outperform at SVB Leerink, Wedbush, and BMO Capital, while being initiated with a Buy at Jefferies. 2. Barings BDC (BBDC) resumed with an Outperform at Wells Fargo. 3. Avedro (AVDR) initiated with an Overweight at JPMorgan while being initiated with an Outperform at SVB Leerink and Cowen. 4. Anchiano Therapeutics (ANCN) initiated with a Buy at Ladenburg and an Outperform at Oppenheimer. 5. CytomX Therapeutics (CTMX) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/19
CANT
05/14/19
INITIATION
Target $21
CANT
Overweight
Cantor starts CytomX with Overweight, sees 'compelling' risk/reward
Cantor Fitzgerald analyst Varun Kumar last night initiated coverage of CytomX Therapeutics with an Overweight rating and $21 price target. The company's lead early-stage clinical assets, based on modified antibodies, are "partially derisked and are highly discounted at the current valuation," Kumar tells investors in a research note. For CX-2009, the analyst thinks clinical updates over the next year months should alleviate investor concerns about its safety profile and that risk of a potential clinical setback is overstated. He sees a "compelling" risk/reward for shares of CytomX.
05/13/19
CANT
05/13/19
INITIATION
CANT
Overweight
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated CytomX Therapeutics with an Overweight rating and $21 price target.
05/13/19
NOMU
05/13/19
NO CHANGE
Target $22
NOMU
Buy
CytomX Therapeutics price target lowered to $22 from $44 at Nomura Instinet
Nomura Instinet analyst Christopher Marai halved his price target for CytomX Therapeutics to $22 but remains a buyer of the stock following the company's Q1 results. Clarification on the '2009 path forward and consistent with CX-072 data will drive share value in 2019 off near all-time-lows, Marai tells investors in a research note. His reduced price target reflects the longer than anticipated trials for '2009 and "limited" '072 updates.
PFE Pfizer
$40.60

-0.12 (-0.29%)

05/09/19
BARD
05/09/19
NO CHANGE
BARD
Outperform
Baird names Sarepta a 'Fresh Pick' ahead of Pfizer data
Baird analyst Brian Skorney named Sarepta as a "Fresh Pick" ahead of the report of competitive data due in late June from Pfizer's (PFE) Duchenne muscular dystrophy program that he predicts will "fall flat." If that turns out to be the case, it should remove the most significant overhang on Sarepta shares, contends Skorney, who keeps an Outperform rating on Sarepta.
05/07/19
ROTH
05/07/19
NO CHANGE
Target $51
ROTH
Buy
Eidos Therapeutics raised to $51 from $28 at Roth Capital
Roth Capital analyst Yasmeen Rahimi raised her price target for Eidos Therapeutics (EIDX) to $51 from $28 driven by an increase in AG10's annual price from $150,000 to $225,000 and Probability of Success adjustment from 70% to 80% after Pfizer's (PFE) tafamadis received U.S. approval with a high sticker price of $225,000, two months ahead of schedule. The analyst believes this makes life easier for Eidos Therapeutics to maintain and even expedite enrollment into its Phase 3 ATTRibute-CM trial. Rahimi reiterates a Buy rating on Eidos Therapeutics shares.
05/14/19
05/14/19
DOWNGRADE
Target $6

Underperform
Solid Biosciences downgraded to Underperform at Credit Suisse
As previously reported, Credit Suisse analyst Martin Auster (SLDB) downgraded Solid Biosciences to Underperform from Neutral as he sees enrollment challenges and pressured timelines ahead. Earlier this year, Solid presented underwhelming initial microdystrophin data for the three patients at the low dose, necessitating dose escalation from 5E13 vg/kg to 2E14 vg/kg, he notes. With another treatment-related SAE, the analyst expects enrollment at this high dose may prove challenging, and notes that while improved efficacy at the higher dose could offset AE issues, promising initial data from Sarepta (SRPT) and positive commentary from Pfizer (PFE) on its Gene Tx program limit upside. Auster also lowered his price target on Solid's shares to $6 from $7.
CGEN Compugen
$3.47

-0.13 (-3.61%)

IMMP Immutep
$1.93

-0.01 (-0.52%)

05/29/18
MAXM
05/29/18
NO CHANGE
Target $7
MAXM
Buy
Immutep price target raised to $7 from $5 at Maxim
Maxim analyst Jason McCarthy raised his price target on Immutep to $7 and kept his Buy rating after the company's announced positive data from the ongoing TACTI-mel study of IMP321. Demonstrating a response rate of 33%, the analyst says the findings validate the IMP321 mechanism of action "and compliment data from the breast cancer study".
09/28/18
RILY
09/28/18
INITIATION
Target $7.75
RILY
Buy
Immutep initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Dylan Dupuis started Immutep with a Buy rating and $7.75 price target. The analyst views the company as a leader in LAG-3 immunotheraphy.
CUE Cue Biopharma
$8.14

0.1 (1.24%)

09/28/18
RILY
09/28/18
INITIATION
Target $14.5
RILY
Buy
Cue Biopharma initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico started Cue Biopharma with a Buy rating and $14.50 price target.
ANIX Anixa Biosciences
$4.50

-0.12 (-2.60%)

10/03/18
10/03/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. XPO Logistics (XPO) initiated with a Buy at Jefferies. 2. Allegiance Bancshares (ABTX) initiated with a Strong Buy at Raymond James. 3. 21Vianet (VNET) initiated with a Buy at Jefferies. 4. Frontdoor (FTDR) initiated with a Buy at Gabelli. 5. Anixa Biosciences (ANIX) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/18
RILY
10/03/18
INITIATION
Target $11.25
RILY
Buy
Anixa Biosciences initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva started Anixa Biosciences with a Buy rating and $11.25 price target. The analyst says the company's novel cancer diagnostics and therapeutics are "flying undetected."
IOVA Iovance Biotherapeutics
$10.18

-0.93 (-8.37%)

04/29/19
PIPR
04/29/19
INITIATION
Target $20
PIPR
Overweight
Iovance Biotherapeutics initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro started Iovance Biotherapeutics with an Overweight rating and $20 price target. The company has "clearly demonstrated the ability to produce a cell therapy with consistent and impressive efficacy in multiple solid tumor settings," Catanzaro tells investors in a research note. He believes response rates of 30%-40% position Iovance for multiple potential approvals over the next five years that include melanoma, cervical cancer, and head and neck cancer.
04/29/19
04/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Iovance Biotherapeutics (IOVA) initiated with an Overweight at Piper Jaffray. 2. Tradeweb Markets (TW) initiated with a Market Perform at Wells Fargo, a Hold at Jefferies and Sandler O'Neill, an Equal Weight at Morgan Stanley and Barclays, as well as a Neutral at BofA/Merrill, Goldman Sachs, Credit Suisse, and Citi. 3. Penn Virginia (PVAC) initiated with an Outperform at Imperial Capital. 4. NGM Biopharmaceuticals (NGM) initiated with an Outperform at Cowen as well as a Buy at Goldman Sachs and Citi. 5. Silk Road Medical (SILK) initiated with an Overweight at JPMorgan, an Outperform at BMO Capital, a Buy at Stifel, and a Neutral at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/07/19
PIPR
05/07/19
NO CHANGE
Target $20
PIPR
Overweight
Iovance Biotherapeutics well positioned in T-cell therapy, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $20 price target on Iovance Biotherapeutics after its Q1 results also disclosed that 3 of its abstracts submitted to ASCO have been accepted. The analyst believes that the company's lifileucel in melanoma update has a "clear opportunity to improve", whiles its LN-145 in cervical cancer data set could be supportive of an accelerated development path. Catanzaro sees Iovance Biotherapeutics as a "best-positioned T-cell therapy" stock, with $440M in cash on hand being sufficient to fund its operations into 2022.
04/03/19
HCWC
04/03/19
NO CHANGE
Target $26
HCWC
Buy
Iovance clinical updates strengthen investment thesis, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis says today's clinical updates from Iovance Biotherapeutics strengthen his investment thesis. The company's efforts to amend clinical programs and generate more powerful tumor-infiltrating lymphocytes therapies are each crucial for gaining market share in multiple clinical indications beyond melanoma, Pantginis tells investors in a research note titled "Important Chess Moves to Head Regulatory Agencies off at the Pass." He believes the advances Iovance is making on multiple fronts, including the clinical and commercial, should be viewed as important inflection points for the shares. The analyst keeps a Buy rating on Iovance Biotherapeutics with a $26 price target.

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

, GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

07:20
05/25/19
05/25
07:20
05/25/19
07:20
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

AMBA

Ambarella

$38.28

1.07 (2.88%)

ON

ON Semiconductor

$17.68

-0.235 (-1.31%)

NKE

Nike

$82.12

-0.51 (-0.62%)

ADDYY

Adidas

$0.00

(0.00%)

UAA

Under Armour

$23.54

0.075 (0.32%)

UA

Under Armour

$20.91

0.08 (0.38%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

VMC

Vulcan Materials

$126.28

1.25 (1.00%)

FLR

Fluor

$29.04

0.18 (0.62%)

ACM

Aecom

$31.56

-0.03 (-0.09%)

X

U.S. Steel

$13.63

-0.08 (-0.58%)

AKS

AK Steel

$2.00

-0.155 (-7.21%)

NUE

Nucor

$51.12

-0.27 (-0.53%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.85

0.11 (0.86%)

F

Ford

$9.83

-0.02 (-0.20%)

GM

General Motors

$35.13

0.01 (0.03%)

HMC

Honda

$25.45

0.175 (0.69%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.54

1.16 (0.99%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CBUS

Cibus

$0.00

(0.00%)

16:25
05/24/19
05/24
16:25
05/24/19
16:25
Syndicate
Cibus requests withdrawal of registration statement »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$355.14

4.57 (1.30%)

16:23
05/24/19
05/24
16:23
05/24/19
16:23
Periodicals
Boeing 737 MAX return delayed by FAA expanding review, WSJ reports »

A review of Boeing's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

FB

Facebook

$181.03

0.14 (0.08%)

, BA

Boeing

$355.14

4.57 (1.30%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. stocks, which had a…

FB

Facebook

$181.03

0.14 (0.08%)

BA

Boeing

$355.14

4.57 (1.30%)

UAL

United Continental

$80.77

-0.14 (-0.17%)

SMI

SMIC

$5.23

-0.26 (-4.74%)

HPQ

HP Inc.

$20.03

0.835 (4.35%)

HPE

HP Enterprise

$14.36

0.03 (0.21%)

NVS

Novartis

$87.49

3.03 (3.59%)

CNC

Centene

$56.84

1.39 (2.51%)

WCG

WellCare

$275.45

0.99 (0.36%)

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

HIBB

Hibbett Sports

$23.91

4.07 (20.51%)

DVAX

Dynavax

$5.77

-0.59 (-9.28%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

SPLK

Splunk

$119.13

-9.55 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 24th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/24/19
05/24
16:17
05/24/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/24/19
05/24
16:16
05/24/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.06

0.09 (4.57%)

16:15
05/24/19
05/24
16:15
05/24/19
16:15
Hot Stocks
Regional Health Properties receives NYSE notice over late Form 10-Q filing »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.